- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
July 15, 2014 (Reuters) -- Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics to track their blood glucose levels or restore the eye's ability to focus.
The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said. The technology is poten
November 1, 2013 (MedGadget) -- Health announced it will begin selling its FDA approved Wireless Smart Gluco-Monitoring System in the US. The device is Bluetooth enabled, allowing a streamlined approach to monitoring, tracking, and sharing of blood glucose levels on iOS and Android tablets and smartphones. The kit comes with a lancet and 50 test strips that require only 0.7mL of blood for a speedy 5 second test, on par with the fastest glucose meters currently on the
March 25, 2013 (Johnson & Johnson) ? At extremely high blood glucose levels (1024 mg/dL and above), the OneTouch VerioIQ Meter will not provide a warning and will shut off Milpitas, CA ? March 25, 2013 ? LifeScan, Inc. is initiating a voluntary recall and replacement for all of its OneTouch VerioIQ blood glucose meters in the United States, effective immediately.
LifeScan is recalling and replacing all OneTouch VerioIQ Meters because at extre
February 28, 2013 (Insulet Corporation) ? Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced financial results for the fourth quarter and full year ended December 31, 2012.
Fourth Quarter Results
Fourth quarter 2012 revenue increased 23% to $57.8 million, compared to $47.2 million in the fourth quarter of 2011. Gross profit for the fourth quarter of 2012 improved by 26% to $25.3 million, as compar
February 28, 2013 (Newswise) ? Some patients are genetically prone to such dangerously high levels of cholesterol that no amount of diet, exercise and medications can reduce their cholesterol to safe levels.
So Loyola University Medical Center is offering a treatment called LDL apheresis, which is similar to kidney dialysis. Once every two weeks, a pa